Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% is a parenteral nutrition solution providing calories (dextrose), amino acids (for protein synthesis), and electrolytes for maintenance of acid-base balance and cellular function. Dextrose is metabolized to glucose, which undergoes glycolysis and oxidative phosphorylation. Amino acids are used for protein synthesis and as an energy source. Electrolytes correct or prevent deficiencies.
Total parenteral nutrition (TPN) solution providing essential amino acids, electrolytes, and dextrose. Dextrose supplies calories to spare protein catabolism; amino acids support protein synthesis; electrolytes maintain acid-base and fluid balance.
Intravenous infusion only. Adult dose determined by nutritional requirements and metabolic tolerance. Typical dose: 500-2000 mL/day infused continuously or intermittently, with dextrose dosage not exceeding 0.5 g/kg/h. Final concentration of dextrose and amino acids must be monitored.
Intravenous administration of 1.5-2.5 L/day in divided doses, adjusted based on metabolic needs, fluid status, and electrolytes. Typical rate: 100-200 mL/hour via central line.
None Documented
None Documented
Dextrose: rapid, minutes (insulin dependent); amino acids: 20-30 min for free pool turnover; electrolytes: distribution half-life 2-4 hours, elimination depends on renal function. Clinical: continuous infusion maintains steady state.
Not applicable as a single entity; components have various half-lives. Glucose has a plasma half-life of approximately 1.5-2 hours. Amino acids have variable half-lives (minutes to hours). Clinical context: continuous infusion maintains steady state.
Primarily renal (glomerular filtration). Dextrose is completely metabolized; electrolytes (sodium, chloride, potassium, calcium, magnesium, acetate) are excreted via kidneys. Acetate is metabolized to bicarbonate. No significant biliary/fecal elimination.
Amino acids and dextrose are metabolized; excess nitrogen is excreted as urea via renal route (approximately 90% of nitrogen output). Electrolytes are excreted renally. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution